Abstract
<p>Supplementary Figure S11. ULMS genomic risk stratification for progression-free survival (PFS). A, A 3-tier genomic risk group is proposed for PFS. PFS for 238 patients with primary ULMS from the MSK cohort with low-, intermediate- and high-risk genomic groups [co-occurrence of TP53 and ATRX mutations or co-occurrence of TP53 mutation and chr20q amplification (amp20q); intermediate risk – presence of any of the following: TP53 mutation, ATRX mutation or amp20q; low risk – lack of any of these three alterations], as well as stratification by tumor size (B), mitotic rate (C), and necrosis (D) are represented by Kaplan-Meier curves.</p>
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
